QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 xilio-therapeutics-hits-175m-milestone-in-gilead-partnership-shares-new-phase-1-data-on-efarindodekin-alfa

In addition, today Xilio announced the achievement of a $17.5 million development milestone under Xilio's license agreement...

 xilio-therapeutics-initiates-patient-dosing-in-phase-2-of-an-ongoing-phase-12-clinical-trial-evaluating-efarindodekin-alfa-as-monotherapy-in-patients-with-certain-advanced-solid-tumors

Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumorsAc...

 xilio-therapeutics-q2-eps-016-misses-008-estimate-sales-8084m-miss-8210m-estimate

Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $...

 reported-earlier-xilio-therapeutics-closes-50m-public-offering-with-potential-to-raise-up-to-150m-through-warrant-exercises-by-2026

Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercise...

 xilio-therapeutics-prices-50m-public-offering-of-pre-funded-warrants-and-series-a-b-c-warrants-to-purchase-667m-shares-each-at-07499-per-unit-co-may-receive-additional-gross-proceeds-from-the-offering-of-up-to-100m-before-deducting-underwriting-discounts-and-commissions-and-offering-expenses

Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno...

 reported-saturday-xilios-tumor-activated-anti-ctla-4-vilastobart-shows-26-objective-response-rate-with-durable-responses-and-low-colitis-in-mss-crc-without-liver-metastases

26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorect...

 xilio-therapeutics-q1-eps-018-misses-010-estimate-sales-293m-miss-440m-estimate

Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION